Literature Review and Practical Aspects on the Management of Oxaliplatin-Associated Toxicity

Hoff, Paulo M.; Saad, Everardo D.; Costa, Frederico; Coutinho, Anelisa K.; Caponero, Ricardo; Prolla, Gabriel; Gansl, Rene Claúdio

doi:10.1016/j.clcc.2011.10.004

Cited by 66 publications

(38 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adding oxaliplatin to fluoropyrimidine chemotherapy results in increased grade 3 or 4 cytopenias and diarrhea, as well as both acute and chronic neurotoxicity. 2,4,6,7 In both NSABP C-07 and MOSAIC, peripheral neuropathy of any grade was observed in more than 60% of patients during oxaliplatin treatment, with 22% of patients reporting symptoms 18 months from random assignment in NSABP C-07 and 15% of patients reporting symptoms at 4 years in MOSAIC. 2,4 Recent studies focused on assessing the long-term consequences of oxaliplatin treatment suggest that chronic neurotoxicity is likely more prevalent than previously reported.…”

Section: 19mentioning

confidence: 99%

“…Concerns over oxaliplatin-induced neuropathy have prompted multiple clinical trials evaluating interventions to mitigate this toxicity. 6,7 With a need to balance limited absolute benefit against significant toxicity, the prevailing paradigm has focused on directing adjuvant therapy to patients at higher recurrence risk, with the expectation of larger absolute treatment benefit. 8,9 Although stage does not predict for the relative benefit of fluorouracil (FU)/leucovorin (LV) or oxaliplatin, stage III patients, compared with stage II patients, have higher recurrence risk and larger absolute treatment benefit.…”

Section: Journal Of Clinical Oncology O R I G I N a L R E P O R T V Omentioning

confidence: 99%

See 1 more Smart Citation

Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus Oxaliplatin

Yothers

O’Connell

Lee

et al. 2013

JCO

149

108

View full text Add to dashboard Cite

A B S T R A C T PurposeAccurate assessments of recurrence risk and absolute treatment benefit are needed to inform colon cancer adjuvant therapy. The 12-gene Recurrence Score assay has been validated in patients with stage II colon cancer from the Cancer and Leukemia Group B 9581 and Quick and Simple and Reliable (QUASAR) trials. We conducted an independent, prospectively designed clinical validation study of Recurrence Score, with prespecified end points and analysis plan, in archival specimens from patients with stage II and III colon cancer randomly assigned to fluorouracil (FU) or FU plus oxaliplatin in National Surgical Adjuvant Breast and Bowel Project C-07. MethodsRecurrence Score was assessed in 892 fixed, paraffin-embedded tumor specimens (randomly selected 50% of patients with tissue). Data were analyzed by Cox regression adjusting for stage and treatment. ResultsContinuous Recurrence Score predicted recurrence (hazard ratio for a 25-unit increase in score, 1.96; 95% CI, 1.50 to 2.55; P Ͻ .001), as well as disease-free and overall survival (both P Ͻ .001). Recurrence Score predicted recurrence risk (P ϭ .001) after adjustment for stage, mismatch repair, nodes examined, grade, and treatment. Recurrence Score did not have significant interaction with stage (P ϭ .90) or age (P ϭ .76). Relative benefit of oxaliplatin was similar across the range of Recurrence Score (interaction P ϭ .48); accordingly, absolute benefit of oxaliplatin increased with higher scores, most notably in patients with stage II and IIIA/B disease. ConclusionThe 12-gene Recurrence Score predicts recurrence risk in stage II and stage III colon cancer and provides additional information beyond conventional clinical and pathologic factors. Incorporating Recurrence Score into the clinical context may better inform adjuvant therapy decisions in stage III as well as stage II colon cancer.

show abstract

Section: 19mentioning

confidence: 99%

Section: Journal Of Clinical Oncology O R I G I N a L R E P O R T V Omentioning

confidence: 99%

Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus Oxaliplatin

Yothers

O’Connell

Lee

et al. 2013

JCO

149

108

View full text Add to dashboard Cite

show abstract

“…The thirdgeneration platinum drug oxaliplatin is typically administered in a combination known as FOLFOX (with fluorouracil and leucovorin) for the treatment of advanced colorectal cancer. Oxaliplatin has less ototoxicity and nephrotoxicity than cisplatin but it can cause an acute painful neuropathy soon after administration (see Hoff et al, 2012), leading to paresthesias (which usually start periorally and then spread to the extremities) and severe cold hypersensitivity. Indeed, exposure to cold can trigger an acute, transient syndrome characterized by cramps, paresthesia, and dysesthesia in patients taking oxaliplatin, presumably by activating TRPA1 .…”

Section: Transient Receptor Potential Channels: Acquired Diseasesmentioning

confidence: 99%

Transient Receptor Potential Channels as Drug Targets: From the Science of Basic Research to the Art of Medicine

2014

View full text Add to dashboard Cite

“…These symptoms are rapidly reversible upon infusion discontinuation even in the absence of treatment (no need for antithistamines, corticoids or bronchodilators), and should be distinguished from hypersensitivity reactions. Other less common side effects include muscle spasms (often jaw spasms), balance disorders, throat or chest pressure/discomfort/pain, and cranial nerve dysfunctions (ptosis, diplopia, dysphonia, abnormal tongue sensation or dysarthria, visual disorders) [53,55] .…”

Section: Oxaliplatinmentioning

confidence: 99%

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy

et al. 2017

Self Cite

View full text Add to dashboard Cite

Systemic chemotherapy is indicated in progressive or bulky advanced pancreatic neuroendocrine tumors (NETs) and in grade 3 (G3) neuroendocrine neoplasms (NENs) as per ENETS guidelines. Chemotherapy may be considered in NETs of other sites (lung, thymus, stomach, colon, and rectum) under certain conditions (e.g., when Ki-67 is at a high level [upper G2 range], in rapidly progressive disease and/or after failure of other therapies, or if somatostatin receptor imaging is negative). An ENETS Consensus Conference was held in Antibes (2015) to elaborate guidelines on the standards of care of different diagnostic procedures and therapeutic interventions in NENs. This article provides guidance on chemotherapy including therapeutic indications, dosing schedules, adverse events (including prevention and management), drug interactions, and evaluation of treatment effect for the chemotherapy agents most commonly used in NENs (streptozocin, dacarbazine, fluoropyrimidines, platinum compounds, etoposide, and irinotecan).

show abstract

Literature Review and Practical Aspects on the Management of Oxaliplatin-Associated Toxicity

Cited by 66 publications

References 75 publications

Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus Oxaliplatin

Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus Oxaliplatin

Transient Receptor Potential Channels as Drug Targets: From the Science of Basic Research to the Art of Medicine

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy

Contact Info

Product

Resources

About